Literature DB >> 17658492

Pituitary adenylate cyclase-activating polypeptide induces pial arteriolar vasodilation through cyclooxygenase-dependent and independent mechanisms in newborn pigs.

Laura Lenti1, Ferenc Domoki, David Kis, Orsolya Hegyi, Gabor K Toth, David W Busija, Ferenc Bari.   

Abstract

Pituitary adenylate cyclase-activating polypeptide (PACAP) is a cerebrovascular dilator and was found neuroprotective in numerous in vitro and in vivo models of cerebral ischemia. However, the mechanism of its cerebrovascular action is poorly known, especially in newborns. Therefore, we tested pial arteriolar responses to the two naturally occurring forms PACAP27 and 38 as well as to shorter sequences (PACAP6-27, 6-38, 1-15, 6-15, 20-31). We also investigated the involvement of nitric oxide synthase (NOS), cyclooxygenase-1 and -2 (COX-1 and -2) activity in PACAP-induced pial arteriolar responses using the NOS inhibitor N-omega-nitro-l-arginine methyl ester (L-NAME 15 mg/kg iv), the non-selective COX inhibitor indomethacin (5 mg/kg iv), and the selective COX-1 and COX-2 inhibitors SC-560 (1 mg/kg iv) and NS-398 (1 mg/kg iv), respectively. Anesthetized, ventilated piglets (n=127) were equipped with closed cranial windows, and pial arteriolar diameters were determined via intravital microscopy. Topical application of both natural PACAPs, but none of the PACAP segments, resulted in prominent, repeatable, dose-dependent vasodilation. Percentage changes ranged 5+/-1-29+/-6 (n=7) and 4+/-1-36+/-7 (n=9) to 10(-)(8) to 10(-)(6) M PACAP27 and 38 (mean+/-SEM), respectively. Vasodilation to both natural PACAPs was significantly reduced by co-application with PACAP6-27 or 6-38, but not by L-NAME. Indomethacin abolished PACAP38 but not PACAP27-induced vasodilation. Arteriolar responses to PACAP38 were also sensitive to SC-560 but not to NS-398 suggesting the unique involvement of COX-1 activity in this response. In summary, PACAP27 and 38 are potent vasodilators in the neonatal cerebral circulation with at least two distinct mechanisms of action: a COX-dependent and a COX-independent pathway.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17658492     DOI: 10.1016/j.brainres.2007.06.032

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  5 in total

1.  PACAP enhances barrier properties of cerebral microvessels.

Authors:  Imola Wilhelm; Csilla Fazakas; Andrea Tamás; Gábor Tóth; Dóra Reglődi; István A Krizbai
Journal:  J Mol Neurosci       Date:  2014-03-11       Impact factor: 3.444

2.  Protective effect of PACAP against doxorubicin-induced cell death in cardiomyocyte culture.

Authors:  Boglarka Racz; Dora Reglodi; Gabriella Horvath; Andras Szigeti; Borbala Balatonyi; Erzsebet Roth; Gyorgy Weber; Nasri Alotti; Gabor Toth; Balazs Gasz
Journal:  J Mol Neurosci       Date:  2010-04-20       Impact factor: 3.444

3.  Characterization of the thermoregulatory response to pituitary adenylate cyclase-activating polypeptide in rodents.

Authors:  Eszter Banki; Eszter Pakai; Balazs Gaszner; Csaba Zsiboras; Andras Czett; Paras Rahul Parkash Bhuddi; Hitoshi Hashimoto; Gabor Toth; Andrea Tamas; Dora Reglodi; Andras Garami
Journal:  J Mol Neurosci       Date:  2014-07-04       Impact factor: 3.444

4.  PACAP and VIP differentially preserve neurovascular reactivity after global cerebral ischemia in newborn pigs.

Authors:  Laura Lenti; Aliz Zimmermann; Dávid Kis; Orsolya Oláh; Gábor K Tóth; Orsolya Hegyi; David W Busija; Ferenc Bari; Ferenc Domoki
Journal:  Brain Res       Date:  2009-06-16       Impact factor: 3.252

Review 5.  Protective effects of PACAP in ischemia.

Authors:  Dora Reglodi; Alexandra Vaczy; Eloísa Rubio-Beltran; Antoinette MaassenVanDenBrink
Journal:  J Headache Pain       Date:  2018-03-02       Impact factor: 7.277

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.